Ombitasvir/paritaprevir/ritonavir

Drug Profile

Ombitasvir/paritaprevir/ritonavir

Alternative Names: ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); VIEKIRA XR; Viekirax

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer AbbVie
  • Class Amides; Anilides; Antiretrovirals; Antivirals; Aza compounds; Carbamates; Cyclopropanes; Phenanthridines; Pyrroles; Pyrrolidines; Small molecules; Sulfones; Thiazoles
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 07 Apr 2017 AbbVie completes a phase III AGATE-I trial in Hepatitis C (Combination therapy, Treatment-experienced, Treatment-naive, In genotype 4 patients with compensated cirrhosis) in USA, Austria, Belgium, Canada, France, Germany, Greece, Italy and Spain (PO) (NCT02265237)
  • 01 Mar 2017 AbbVie completes the phase III ONYX-II trial in Hepatitis C (Combination therapy) in China, Taiwan, South Korea (PO) (NCT02517528)
  • 01 Mar 2017 AbbVie completes the phase III TURQUOISE-CPB trial in Hepatitis C (Combination therapy) in Germany, Canada and USA (NCT02219477)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top